Neurocrine Biosciences (NBIX) Operating Margin (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Operating Margin (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -795.00 |
| Mar 31, 2026 | -244.00 |
| Dec 31, 2025 | -388.00 |
| Sep 30, 2025 | 889.00 |
| Jun 30, 2025 | 1,706.00 |
| Mar 31, 2025 | -1,850.00 |
| Dec 31, 2024 | -692.00 |
| Sep 30, 2024 | 491.00 |
| Jun 30, 2024 | 537.00 |
| Mar 31, 2024 | -990.00 |
| Dec 31, 2023 | 87.00 |
| Sep 30, 2023 | 1,205.00 |
| Jun 30, 2023 | 4,342.00 |
| Mar 31, 2023 | -5,226.00 |
| Dec 31, 2022 | 246.00 |
| Sep 30, 2022 | 817.00 |
| Jun 30, 2022 | 1,347.00 |
| Mar 31, 2022 | 1,263.00 |
| Dec 31, 2021 | -2,667.00 |
| Sep 30, 2021 | -670.00 |